Results 1 to 10 of about 3,791 (213)

Posology for 177Lu-DOTATATE Therapy in Neuroendocrine Tumor: Effectiveness of Dose Reduction and Cycle Delay for Improving Therapy Tolerability. [PDF]

Clin Nucl Med
Approval of 177Lu-DOTATATE for the treatment of neuroendocrine tumors (NETs) requires monitoring for therapeutic efficacy and safety. A retrospective review was conducted on 173 patients who received 177Lu-DOTATATE at the University of Michigan to ...
Wang IE, Patterson J, Akhavanallaf A, Lu Z, Viglianti BL, Roseland M, Muhleman M, Frey KA, Scott PJH, Dewaraja YK, Wong KK.   +10 more
europepmc   +2 more sources

First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma

EJNMMI Reports
Radiotheranostics using somatostatin receptor (SSTR)-targeted agents has transformed the management of neuroendocrine tumors, yet its application in other oncological entities remains unexplored.
Wendy Delbart, Marie Vercruyssen, Rachele Danieli, Clémentine Marin, Zéna Wimana, Nathalie Meuleman, Patrick Flamen, Erwin Woff, Ioannis Karfis   +8 more
doaj   +1 more source

The therapeutic efficacy of 225Ac-DOTATATE in neuroendocrine tumors: a preliminary meta-analysis

Frontiers in Oncology
ObjectiveThis meta-analysis aims to evaluate the therapeutic efficacy and toxicity of 225Ac-DOTATATE in patients with metastatic neuroendocrine tumors (NETs).MethodsThis systematic review adheres to the Preferred Reporting Items for Systematic Reviews ...
Jiao Ma, Jiao Ma, Jiao Ma, Yang Ji, Yang Ji, Yang Ji, Zhihan Yao, Zhihan Yao, Zhihan Yao, Jiangchu Yangqing, Jiangchu Yangqing, Jiangchu Yangqing, Chunyin Zhang, Chunyin Zhang, Chunyin Zhang   +14 more
doaj   +1 more source

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

Frontiers in Oncology
Meningiomas are the most common primary intracranial tumor in adults. Beyond surgery and radiation, no standard of care therapy exists. Meningiomas overexpress somatostatin receptor 2 (SSTR2), providing the rationale for somatostatin analogue-based ...
Carlen A. Yuen, Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, David O. Kamson, Eleanor Chu, Eleanor Chu, Jennifer E. Soun, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Frank P. Hsu, Hansen Bow, Hansen Bow, Michelle Zheng, Shyam M. Srinivas   +15 more
doaj   +1 more source

Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy

, 2019
Molecular radiotherapy using 177Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the time of treatment planning or delivery. On positive uptake on octreotide-based PET/SPECT imaging,
O'Neill, Edward, Kersemans, Veerle, Allen, P Danny, Terry, Samantha Yorna Armstrong, Baguna Torres, Julia, Mosley, Michael, Smart, Sean, Quan Lee, Boon, Falzone, Nadia, Vallis, Katherine, Konijnenberg, Mark, de Jong, Marion, Nonnekens, Julie, Cornelissen, Bart   +13 more
openaire   +2 more sources

Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis

Thyroid Research
This systematic review and meta-analysis evaluated the safety and efficacy of somatostatin receptor (SSTR) peptide receptor radionuclide therapy (PRRT) in patients with metastatic or progressive medullary thyroid cancer (MTC).
Ahmed Saad Abdlkadir, Dhuha Al-Adhami, Hongcheng Shi, Mike Machaba Sathekge, Areej Abu Sheikha, Issa Mohamad, Michael Kreissl, Akram Al-Ibraheem   +7 more
doaj   +1 more source

A Dosimetrist Performance Analysis on the Dosimetry of 177Lu-DOTATATE Radionuclide Treatment

Advances in Medical Pyhsics and Applied Sciences
The accuracy of the PRRT dosimetric procedure depends on the dosimetrist's personal skills in the step of determining the accumulated activity in the relevant organ.  The detection of activity involvement is done manually by the dosimetrist using a mouse on SPECT images. Creating custom ROIs may create differences in dosimetric calculations.
Abrar Qasım Mustafa AL RAMADHANI, Bilal KOVAN, Serkan KUYUMCU, Bayram DEMİR   +3 more
openaire   +1 more source

PCN132 Cost-Effectiveness Analysis of RE-Treatment with 177lu-Dotatate Versus NO RE-Treatment with 177lu-Dotatate in Patients with Progressive Midgut Neuroendocrine Tumors [PDF]

Value in Health, 2020
O. Leeuwenkamp, R. Mahon, M.K. Singh, A. Khare   +3 more
openaire   +1 more source

Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model. [PDF]

Mol Cancer Ther, 2023
Sharma R, Earla B, Baidoo KE, Zeiger MA, Madigan JP, Escorcia FE, Sadowski SM.   +6 more
europepmc   +1 more source

Validation of Simplified Renal Dosimetry Protocols for ¹⁷⁷Lu-DOTATATE Therapy Using the IDAC-dose Software. [PDF]

Mol Imaging Radionucl Ther
Yokouchi A, Shibutani T, Konishi T, Yoneyama H, Ichikawa H, Wakabayashi H.   +5 more
europepmc   +1 more source